Browse > Article

Enhanced Solubility and In vitro Skin Permeation of Lovastatin Using Some Vehicles and Penetration Enhancers  

Lee, Na Young (College of Pharmacy, Dongduk Women's University)
Chun, In Koo (College of Pharmacy, Dongduk Women's University)
Publication Information
YAKHAK HOEJI / v.58, no.3, 2014 , pp. 171-180 More about this Journal
Abstract
To enhance the in vitro permeation of lovastatin through excised hairless mouse and human cadaver skins, solubility was determined in various hydrophilic and lipophilic vehicles, and the effects of vehicles and penetration enhancers on the skin permeation from solution formulations were investigated. Solubility of lovastatin was highest in N-methyl-2-pyrrolidone (NMP) ($278.2{\pm}10.1$ mg/ml) and dimethyl sulfoxide (DMSO) ($162.2{\pm}9.7$ mg/ml). Among different pure vehicles used, NMP, DMSO, propylene glycol and isopropyl myristate provided some drug permeation ($6.9{\pm}1.1$, $5.9{\pm}1.6$, $3.0{\pm}0.5$ and $2.2{\pm}0.3{\mu}g/cm^2$ at 24 hr, respectively) through hairless mouse skin. The addition of oleic acid, linoleic acid and oleyl alcohol to DMSO showed the maximum permeation at around 5 v/v%, however, capric acid and caprylic acid had no enhancing effect. The increase of enhancer concentrations showed bell-shaped permeation rate, suggesting the presence of optimal concentration in lovastatin penetration. Increasing donor concentration from 10 mg/ml to 80 mg/ml in DMSO and a cosolvent of DMSO, NMP and DGME (3 : 3 : 4 v/v) did not show significant dose dependent permeation in both hairless mouse and human cadaver skins. The maximum lovastatin flux through human cadaver skin was found to be $0.87{\pm}0.46{\mu}g/cm^2$/hr with 5 v/v% linoleic acid and donor dose of 4 mg/0.64 $cm^2$ in the cosolvent. These results suggest that transdermal delivery of lovastatin would be feasible by establishing the optimal concentrations of donor dose and unsaturated fatty acids in appropriate vehicles.
Keywords
lovastatin; solubility; skin permeation; vehicles; enhancers;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Xia, Z., Tan, M. M., Wei-Lynn Wong, W., Dimitroulakos, J., Minden, M. D. and Penn, L. Z. : Blocking protein prenylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15, 1398 (2001).   DOI
2 Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R. and Bernini, F. : New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413 (1999).   DOI   ScienceOn
3 Shitara, Y. and Sugiyama, Y. : Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71 (2006).   DOI   ScienceOn
4 Chuengsamarn, S., Rattanamongkoulgul, S., Suwanwalaikorn, S., Wattanasirichaigoon, S. and Kaufman, L. : Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 46, 1011 (2010).   DOI   ScienceOn
5 Jacobs, R. J., Voorneveld, P. W., Kodach, L. L. and Hardwick, J. C. H. : Cholesterol metabolism and colorectal cancers. Current Opinion Pharmacol. 12, 690 (2012).   DOI   ScienceOn
6 Gauthaman, K., Fong, C. Y. and Bongso, A. : Statins, stem cells, and cancer, J. Cell. Biochem. 106, 975 (2009).   DOI   ScienceOn
7 Silva, M. A., Swanson, A. C., Gandhi, P. J. and Tataronis, G. R. : Statin-related adverse events: A meta-analysis. Clin. Ther. 28, 26 (2006).   DOI   ScienceOn
8 Wortmann, R. L., Tipping, R. W., Levine, J. G. and Melin, J. M. : Frequency of myopathy in patients receiving lovastatin. Am. J. Cardiol. 95, 983 (2005).   DOI   ScienceOn
9 Bellosta, S., Paoletti, R. and Corsini, A. : Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109, III50 (2004).   DOI   ScienceOn
10 Patel, R. P. and Patel, M. M. : Solid-state characterization and dissolution properties of lovastatin hydroxypropyl-${\beta}$-cyclodextrin inclusion complex. Pharm. Technol. 31, 72 (2007).
11 Suresh, G., Manjunath, K., Venkateswarlu, V. and Satyanarayana, V. : Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm. Sci. Technol. 8, E1 (2007).
12 Mehramizi, A., Asgari Monfared, E., Pourfarzib, M., Bayati, Kh., Dorkoosh, F. A. and Rafiee-Tehrani, M. : Influence of ${\beta}$-cyclodextrin complexation on lovastatin release from osmotic pump tablets (OPT). DARU 15, 71 (2007).
13 Wu, C., Wang, Z., Zhi, Z., Jiang, T., Zhang, J. and Wang, S. : Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs. Int. J. Pharm. 403, 162 (2011).   DOI   ScienceOn
14 Patel, M., Tekade, A., Gattani, S. and Surana, S. : Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques, AAPS Pharm. Sci. Technol. 9, 1262 (2008).   DOI   ScienceOn
15 Alverts, A. W. : Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol., 62, J10 (1998).
16 Manzoni, M. and Rollini, M. : Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol. 58, 555 (2002).   DOI   ScienceOn
17 Chen, C. C., Tsai, T. H., Huang, Z. R. and Fang, J. Y. : Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm. 74, 474 (2010).   DOI   ScienceOn
18 Zawar, L. R., Bhandari, G. S. and Bari, S. B. : Formulation and evaluation of transdermal film of lovastatin. Res. J. Pharm. Biol. Chem. Sci. 2, 575 (2011).
19 Chun, I. K. : Dissolution and duodenal permeation characteristics of lovastatin from bile salt solid dispersions. J. Kor. Pharm. Sci. 39, 97 (2009).   과학기술학회마을   DOI   ScienceOn
20 Shinde, A. J., Paithane, M. B. and More, H. N. : Development and in vitro evaluation of transdermal patches of lovastatin as a antilipidemic drug. Int. Res. J. Pharm. 1, 113 (2010).
21 Sharma, S., Sharma, A., Arora, S. and Gupta, A. : Preparation, characterization, in vitro & in vivo evaluation of elastic liposomal formulation of lovastatin. J. Pharm. Res. 4, 4074 (2011).
22 Sarvaiya, J. I., Kapse, G. K. and Tank, C. J. : Iontophoresis of micellar composition of lovastatin: study of affecting factors and in vitro permeation. J. Pharm. Res. 7, 327 (2013).   DOI
23 Kumar, R. and Philip, A. : Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Trop. J. Pharm. Res. 6, 633 (2007).
24 Gwak, H. S. and Chun, I. K. : Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int. J. Pharm. 236, 57 (2002).   DOI
25 Lee, J. H. and Chun, I. K. : Effects of various vehicles and fatty acids on the skin permeation of lornoxicam. J. Pharm. Invest. 42, 235 (2012).   과학기술학회마을   DOI
26 Lovastatin Tablets, The United States Pharmacopeia, Volume II, The United Book Press, Baltimore, pp. 2815-2817 (2009).
27 Alvarez-Lueje, A., Pastine, J., Squella, J. A. and Nunez-Vergara, L. J. : Assessment of the hydrolytic degradation of lovastatin by HPLC. J. Chil. Chem. Soc. 50, 639 (2005).
28 Yang, D. J. and Hwang, L. S. : Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-Erh tea. J. Chromatogr. A 1119, 277 (2006).   DOI   ScienceOn
29 Kligman, A. M. : Topical pharmacology and toxicology of dimethyl sulfoxide. J. Am. Med. Assoc. 193, 796 (1965).   DOI   ScienceOn
30 Huang, Z., Xu, Y., Li, Y. and Wang, Y. : Conversion investigation for lovastatin and its derivatives by HPLC. J. Chromatogr. Sci. 48, 631 (2010).   DOI
31 Barry, B. W. : Dermatological Formulations: Percutaneous Absorption, Marcel Dekker, New York, pp. 49-94 (1983).
32 Serajuddin, A. T., Ranadive, S. A. and Mahoney, E. M. : Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80, 830 (1991).   DOI
33 Williams, A. C. and Barry, B. W. : Penetration enhancers. Adv. Drug Del. Rev. 56, 603 (2004).   DOI   ScienceOn
34 Ganem-Quintanar, A., Lafforgue, C., Falson-Rieg, F. and Buri, P. : Evaluation of the transepidermal permeation of diethylene glycol monoethyl ether and skin water loss. Int. J. Pharm. 147, 165 (1997).   DOI   ScienceOn
35 Mura, P., Faucci, M. T., Bramanti, G. and Corti, P. : Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur. J. Pharm. Sci. 9, 365 (2000).   DOI   ScienceOn
36 Hoelgaard, A., Mollgaard, B. and Baker, E. : Vehicle effect on topical drug delivery. IV. effect of N-methylpyrrolidone and polar lipids on percutaneous drug transport, Int. J. Pharm. 43, 233 (1988).   DOI
37 Golden, G. M., McKie, J. E. and Potts, R. O. : Role of stratum corneum lipid fluidity in transdermal drug flux. J. Pharm. Sci. 76, 25 (1987).   DOI
38 Komata, Y., Kaneko, A. and Fujie, T. : In vitro percutaneous absorption of thiamine disulfide through rat skin from a mixture of propylene glycol and fatty acid or its analog. Chem. Pharm. Bull. 40, 2173 (1992).   DOI   ScienceOn
39 Roy, S. D., Hou, S.-Y. E., Witham, S. L. and Flynn, G. L. : Transdermal delivery of narcotic analgesics: comparative metabolism and permeability of human cadaver skin and hairless mouse skin. J. Pharm. Sci. 83, 1723 (1994).   DOI   ScienceOn
40 Santoyo, S. and Ygartua P. : Effect of skin pretreatment with fatty acids on percutaneous absorption and skin retention of piroxicam after its topical application. Eur. J. Pharm. Biopharm. 50, 245 (2000).   DOI   ScienceOn
41 Andega, S., Kanikkannan, N. and Singh, M. : Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin. J. Controled Release 77, 17 (2001).   DOI   ScienceOn
42 Oertel, R. P. : Protein conformational changes induced in human stratum corneum by organic sulfoxides: an infrared spectroscopic investigation. Biopolymers 16, 2329 (1977).   DOI   ScienceOn
43 Ghosh, B., Reddy, L. H., Kulkarni, R. V. and Khanam, J. : Comparison of skin permeability of drugs in mice and human cadaver skin. Indian J. Exp. Biol. 38, 42 (2000).
44 Godin, B. and Touitou, E. : Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv. Drug Del. Rev. 59, 1152 (2007).   DOI   ScienceOn